This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.
Are able to understand and provide written informed consent document.
Are Chinese males aged ≥ 18 years.
Have histopathologically confirmed prostate adenocarcinoma and have undergone radical prostatectomy and/or radical radiotherapy and experienced biochemical recurrence (PSA should be measured within 30 days of screening).
Post radical prostatectomy (RP) PSA ≥0.2 ng/mL measured 6 weeks after RP
Have a prior history of any other malignancy within the last year, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.
Have prior use of radionuclides with an interval of less than 10 physical half-lives before the administration of 68Ga-PSMA-11.
Are participating or plan to participate in any drug or device clinical study during the study period.
Have a known hypersensitivity to the active ingredient or its components of 68Ga-PSMA-11.
Telix Pharmaceuticals (Innovations) Pty Limited
Lead sponsor
Grand Pharmaceutical (China) Co., Ltd.
Collaborator